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ABSTRACT:  We evaluated the effects of Nicotine Replacement Therapy
(NRT) on the Profile of Mood States (POMS), testing whether pre-cessation
depressive symptoms modify NRT’s effects on POMS. Out of 608 smokers
attempting to quit with NRT, this secondary analysis included 242 participants
abstinent  for  at  least  two  weeks.  We  measured  pre-cessation  depressive
symptoms with the Center for Epidemiological Studies Depression Scale. At 1,
7, and 14 post-cessation days we examined 6 self-reported POMS, i.e. feeling
‘anxious’, ‘sad’, ‘confused’, ‘angry’, ‘energetic’ and ‘fatigue’. The results of
the ANCOVA models suggested no NRT effects on feeling anxious, energetic
or fatigue. We found that pre-cessation depression modified NRT effects in
some specific mood states, such as depression by NRT- interaction effects on
feeling confused and feeling angry. On average, the depressed participants in
the placebo groups had the highest symptom scores. However, those depressed
in NRT conditions did not have significantly higher symptom scores compared
to the non-depressed groups. In treating those negative moods NRT may be
particularly important for persons with depressive symptoms before cessation.
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INTRODUCTION
Prolonged tobacco use triples mortality
rates, whereas smoking cessation halves
or  even  avoids  those  hazards  [1].
According to the PHS Clinical Practice
Guidelines [2] two main treatments for
tobacco  dependence  are  behavioural
counselling and pharmacotherapy.   Six
first-line pharmaco-therapies have been
identified  that  increase  smoking
abstinence,  such  as  five  forms  of
nicotine  replacement  therapy  (NRT),
including nicotine gum, inhaler, nasal
spray,  patch,  and  lozenge,  and  non-
nicotine bupropion SR.
Most  smokers  would  like  to  stop
smoking, but for many of them it is very
difficult  because  of  withdrawal
symptoms [2]. According to the DSM-18 Korhonen
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IV  diagnostic  criteria  for  nicotine
withdrawal  [3],  the  symptoms  can
appear within two hours after the last use
of tobacco, and usually last from a few
days  to  four  weeks.  Among  the
withdrawal  signs  several  measurable
symptoms  have  been  identified,  i.e.
depressed mood, insomnia, irritability,
anxiety,  difficulty  concentrating,
restlessness, decreased heart rate, weight
gain and craving [4]. These withdrawal
signs  may  be  conceptualized  as
cognitive,  affective,  somatic,  and
craving, although they are not mutually
exclusive.   For  example,  difficulty
concentrating  and  impaired  cognitive
performance are identified as part of the
nicotine  withdrawal  syndrome  [3].
Further,  mood  related  withdrawal
symptoms,  such  as  depressed  mood,
anxiety  and  irritability,  remain  major
impediments  for  smoking  cessation,
early  relapse  being  associated  with
increase in negative mood [5]. Although
not directly measuring the withdrawal
symptomatology as listed in the DSM-
IV  diagnostic  criteria  for  nicotine
withdrawal  [3],  the  Profile  of  Mood
States (POMS) [6] can be used to track
most  nicotine  withdrawal  signs.
According to Ward et al. [7], the POMS,
including  three  affective  (feeling
anxious,  sad,  angry),  one  cognitive
(feeling  confused)  and  two  somatic
energy-related  (feeling  energetic,
fatigue) states of mood, can be identified
as transient abstinence effects during the
first month after cessation.
The efficacy of NRT for smoking
cessation is well established [2]. One of
mechanisms by which NRT may work is
by  reducing  affective,  cognitive  and
somatic  symptoms  during  abstinence
from  smoking  [4].  However,  some
studies  have  observed  only  limited
effects  [8,  9],  whereas  some  studies
suggest  that  NRT  has  a  favourable
impact on negative mood and facilitate
attention [10,11].
Smokers  with  psychiatric  co-
morbidities,  including  depressive
symptoms, have been mentioned as a
special  subgroup  requiring  additional
research  within  efficacy  of  tobacco
dependence treatments [2]. Also, there
has  been  substantial  variability  in
treatment  response  among  various
subgroups of quitters, such as smokers
with  co-morbidities  [4].  These  recent
developments challenge to analyze more
specifically how NRT works in those
subgroups.
Concerning  depressive  symptoms,
some recent studies have suggested that
a history of lifetime depression would
not be a risk factor for smoking relapses
[12, 13]. However, current depressive
symptoms  are  suggested  to  be
impediments for quitting and smoking
may function as a self-medicating device
for those with such symptoms [14, 15].
Also,  currently  depressed  individuals
smoke  more  frequently  and  are  more
dependent than non-depressed [16, 17,
18].  Further,  smokers  with  current
depression have lower cessation rates
than  non-depressed  [18,  19]  and
smoking cessation may elicit depression
among  patients  with  prior  affective
disorder [17, 20, 21]. Concerning NRT
efficacy  for  depressed  smokers,  the
effects of nicotine gum on abstinence
have been found particularly beneficial
among  the  depressed  quitters  [22].
However, there has been little evidence
on  effects  of  nicotine  treatment  on
mood,  such  as  POMS,  among
participants  with  Major  Depressive
Disorder [23]. Previous research raises a
further question whether pre-cessation
depressive  symptoms  modify  NRT
effects on post-cessation mood duringImpact of Nicotine Replacement Therapy on Post-Cessation Mood Profile by Pre-Cessation
Depressive Symptoms 19
the abstinence, i.e. if there is interaction
between  treatment  and  pre-cessation
depressive symptoms. Following these
challenges, the aim of this study was to
investigate  whether  pre-cessation
depressive  symptoms  modify  NRT
effects on post cessation mood states.
METHODS
Sample and Procedures
The  current  data  are  from  a
randomized controlled nicotine gum trial
that took place during the period 1992-
1996 in Boston, MA, USA. The original
sample included 608 smokers attempting
to  quit.  Before  their  quit  days,
participants were randomly assigned into
a  NRT  (2  or  4  mg  nicotine  gum)  or
placebo (0 mg placebo gum) condition.
All  participants  were  provided  brief
counselling.  Details  of  the  trial
procedures and main results have been
previously reported [24].
The  current  study  is  a  secondary
analysis including 242 participants who
remained abstinent for at least 2 weeks
(39.8%  of  the  original  sample).  Self-
reported  abstinence  was  verified  by
carbon monoxide (CO) measurements.
Relapse in this study was defined as a
return to a regular pattern of smoking,
i.e. seven or more consecutive days or
episodes  of  smoking  [25].  Figure  1
shows  the  flow  chart  of  the  studied
subgroups by depression and treatment
condition analyzed in this study.
Measures
In order to categorize our sub-sample
into  “depressed’  and  ‘non-depressed’
participants before quitting smoking we
used the data collected at the baseline
visit.  To  measure  pre-cessation
depressive symptoms we used the Centre
for Epidemiological Studies Depression
Scale (CES-D) [26, 27]. It is a widely
used self-report instrument including 20
items on frequency and severity of given
symptoms  a  person  had  experienced
during the past week. Four items were
first reverse-scored and then summed to
create a depression score (ranging from
0 to 60). To be classified as ‘depressed’,
participants had to have a CES-D score
of at least 16; to be categorized as ‘non20 Korhonen
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depressed’, participants had to have a
CES-D score of less than 16.  The cut-
off of 16 is considered a standard for
current depression, although somewhat
higher scores have been suggested as
well [28]. However, labelling those with
low CES-D score as ‘non depressed’ and
those  with  high  CES-D  score  as
‘depressed’ was used more for brevity
through  the  paper  rather  than  for
referring to depression diagnosis.
As proxy for withdrawal symptoms
we  investigated  six  mood-related
symptoms at 1, 7 and 14 post-cessation
days. These self-reported measures were
adopted from the Profile of Mood States
(POMS) [6] to examine four affective
and  cognitive  symptoms:  ‘feeling
anxious’,  ‘feeling  sad’,  ‘feeling
confused’ and ‘feeling angry’, as well as
two energy-related symptoms: ‘feeling
energetic’  and  ‘feeling  fatigue’.   The
actual  questions  for  each  item  were
worded as follows: “How anxious/ sad
or  depressed/  confused/
angry/energetic/fatigued have you felt
during  the  past  24  hours?”  Possible
responses for each item ranged from 0
(not  at  all)  to  4  (extremely).  Similar
measures  for  subjective  mood  related
withdrawal symptoms during smoking
cessation have been successfully applied
in  an  earlier  analysis  of  the  same
research study [24].
Statistical Analyses
For  descriptive  analyses  we
employed  Chi-Square  tests  for
categorical variables and t tests for age,
Fagerström Test of Nicotine Dependence
(FTND), POMS and CES-D scores. To
assess the effects of NRT and depression
on the post-cessation mood symptoms
we  conducted  a  set  of  mixed-design
repeated  measures  analyses  of
covariance (ANCOVA) for each POMS
variable. The main models included all
main effects, i.e. depression, NRT and
time, the baseline POMS measure as a
covariate, plus all interactions. For all
POMS  the  scores  were  computed
separately  among  the  participants
scoring  high  (‘depressed’)  and  low
(‘non-depressed’)  in  the  pre-cessation
depressive  symptoms.  The  results  of
covariance  analysis  models  give
estimates how significant, on average,
each factor, i.e. NRT, depression, time,
or  any  interaction,  is  in  the  model.
Further, in order to identify significant
pair-wise  differences  at  specific  time
points,  i.e.  at  1,  7,  and14  days,  we
computed  the  Tukey  HSD  Post  Hoc
tests,  which  are  suitable  and  reliable
tests  for  multiple  tests  between  may
subsamples  [29].  Analyses  were
performed  using  SAS  v.  8.02  for
Windows  and  Statistica  v.  6.1  for
Windows.
RESULTS
Drop-out Analysis
Table  1  shows  comparison  of
selected baseline characteristics between
the participants included in this analysis
(i.e. abstinent for at least 2 weeks) and
those who were excluded (i.e. relapsed
before 2 weeks). There were significant
differences between abstinent and non
abstinent  samples  in  the  number  of
cigarettes per day (p =.01), in nicotine
dependence  measured  by  the  FTND
score (p =.0001), in feeling sad (p =.006)
and  fatigue  (p  =.003),  as  well  as  in
baseline depression score (CES-D) (p
=.003).   Those  not  included  scored
higher  in  tobacco  consumption  and
dependence,  as  well  as  in  baseline
moods, such as feeling sad and fatigue
and in baseline depression score.Impact of Nicotine Replacement Therapy on Post-Cessation Mood Profile by Pre-Cessation
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TABLE 1.  Baseline characteristics among the participants abstinent for at least 14 days
and those abstinent for less than 14 days.
Abstinent
(n=242)
Non abstinent
(n= 366) P value
a
Socio-demographics
Gender (% of male) 52.1 46.4 .17
Age (years)
b 41.5 (12.1) 40.4 (11.7) .24
Race (%)
White
African American
Other
81.4
11.6
7.0
80.6
13.9
5.5
.27
Marital Status (%)
Single
Married
Divorced/separated/widowed
39.7
33.5
26.8
46.4
26.0
27.6
.24
Education (%)
Less than 12 years
12-15 years
16 or more years
3.7
50.4
45.9
6.0
56.3
37.7
.11
Smoking characteristics
Cigarettes per day 21.7 (10.0) 24.7 (11.7) .0008
FTND (range 1-10) 5.1 (2.2) 5.8 (2.3) .0001
POMS
 c
Feeling anxious 1.4 (1.1) 1.5 (1.2) .36
Feeling sad 0.6 (0.8) 0.9 (1.0) .002
Feeling confused 0.4 (0.8) 0.6 (0.9) .07
Feeling angry 0.8 (1.0) 0.9 (1.1) .48
Feeling energetic 2.0 (1.0) 1.8 (1.0) 0.08
Feeling fatigue 1.3 (1.1) 1.6 (1.2) 0.003
Depression score (range 0-60) 11.3 (9.0) 13.7 (10.2) 0.003
a Chi-Square test, except t test for age, FTND, POMS and CES-D.
b Values are means with standard deviations in parentheses
c POMS= Profile of Mood Score
Participant Characteristics
The  prevalence  of  baseline
depressive symptoms was 32.2 % in the
original sample (n=608), whereas 26.0%
among the participants included in this
analysis  (n=242)  (p<.001).  The
participant characteristics of the current
study by treatment condition are shown
in Table 2 separately for the depressed
and the non-depressed groups. The only
significant  difference  was  in  racial
categories. Among the depressed group
fewer  white  participants  were  in  the
placebo than in the NRT condition (p
=.05). As shown in Table 2, there were
large differences between depressed and
non-depressed on most POMS variables
at  baseline.  Thus,  all  the  analyses
included baseline score as a covariate.22 Korhonen
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TABLE 2.  Baseline Characteristics by Treatment for the Depressed and Non-depressed among
the Participants (n=242)
Depressed
a
(n=63 )
Not Depressed
b
(n=179)
Gender (% of male) 40.0 61.5 .16 53.3 59.1 .50
Age (years)
d 40.1(11.3) 40.8(6.4) .85 42.5(12.0) 40.4(11.6) .32
Race (%)
White
African American
Other
83.7
12.6
3.7
72.7
13.6
13.6
.05
82.0
8.0
10.0
84.6
7.7
7.7
.97
Marital Status (%)
Single
Married
Divorced/separated/widowed
50.0
24.0
26.0
38.5
30.8
30.8
.75
35.6
34.8
29.6
40.9
40.9
18.2
.33
Education (%)
Less than 12 years
12-15 years
16 or more years
4.0
52.0
44.0
7.7
53.8
38.5
.83
3.7
51.1
45.2
2.3
45.5
52.3
.68
Smoking characteristics
Cigarettes per day 22.7(12.2) 23.2(7.5) .91 21.9 (9.6) 19.8( 6.9) .22
FTND (range 1-10) 5.6 (2.2) 4.8 (1.9) .29 5.0 (2.2) 4.7 (2.5) .39
POMS
e
Feeling anxious 1.8 (1.1) 2.0 (1.2) .61 1.3 (1.1) 1.1 (0.9) .38
Feeling sad 1.3 (1.0) 1.1 (0.8) .59 0.3 (0.6) 0.6 (0.9) .09
Feeling confused 0.9 (1.1) 0.9 (0.9) .95 0.3 (0.5) 0.2 (0.6) .93
Feeling angry 1.4 (1.3) 1.5 (1.0) .91 0.6 (1.0) 0.6 (0.9) .67
Feeling energetic 1.8 (1.1) 1.7 (0.8) .66 2.0 (1.0) 2.1 (0.6) .49
Feeling fatigue 1.8 (1.2) 1.8 (1.0) .80 1.1 (1.0) 1.3 (1.1) .17
Depression score (range 0-60) 23.9 (7.2) 23.6(4.9) .90 6.8 (4.4) 7.3 (4.1) .54
a CES-D>15 
b CES-D≤15
c Chi-Square test, except t test for age, FTND, POMS and CES-D.
d Values are means with standard deviations in parentheses
e POMS= Profile of Mood ScoreImpact of Nicotine Replacement Therapy on Post-Cessation Mood Profile by Pre-Cessation
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TABLE 3. Results of the repeated measures ANCOVA main models
FEELING
ANXIOUS
FEELING
 SAD
FEELING
CONFUSED
FEELING
ANGRY
FEELING
ENERGETIC
FEELING
FATIGUE
df F p F p F p F p F p F p
BASELINE
SCORE
1 29.15 <.001 24.80 <.001 42.63 <.001 44.30 <.001 54.50 <.001 23.51 <.001
NRT 1 010 .76 4.48 .03 9.45 .002 3.51 .06 2.81 .09 1.07 .30
CES-D
a 1 4.78 .03 9.83 .002 14.02 <.001 10.68 .001 0.08 .77 1.88 .17
NRT * CES-D
a 1 0.22 .64 3.55 .06 8.17 .005 5.47 .02 0.00 .95 1.38 .24
TIME 2 1.10 .33 0.51 .60 1.14 .32 4.16 .02 1.10 .33 0.08 .92
NRT * TIME 2 0.15 .86 0.65 .52 0.44 .65 2.78 .06 0.47 .62 1.74 .17
CES-D
a * TIME 2 0.46 .63 0.05 .95 0.92 .40 1.15 .32 2.74 .06 0.66 .52
CES-D
a * NRT *
TIME
2 1.71 .18 0.02 .98 2.08 .13 0.67 .51 1.12 .32 2.22 .11
a As a dichotomy in the model (CES-D>15 = ’depressed’; CES-D ≤15 = ‘not depressed’
Effects of NRT on POMS
The results of the main effects of
NRT, depressive symptoms and time on
the  post-cessation  mood  symptoms
(feeling anxious, sad, confused, angry,
energetic, and fatigue) as well as those
interactions are shown in Table 3. Based
on  the  repeated  measures  ANCOVA
analyses, figures 2 – 5 show the sets of
curves for the observed average POMS
scores  at  baseline,  1,  7  and  14  post-
cessation  days  by  the  treatment
condition  (NRT/Placebo)  and  by  the
baseline  depressive  symptoms  status
(‘non-depressed’ / ‘depressed’), where
significant  effects  were  found
analyses, figures 2 – 5 show the sets of
curves for the observed average POMS
scores  at  baseline,  1,  7  and  14  post-
cessation  days  by  the  treatment
condition  (NRT/Placebo)  and  by  the
baseline  depressive  symptoms  status
(‘non-depressed’ / ‘depressed’), where
significant  effects  were  found.24 Korhonen
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Feeling anxious
In feeling anxious no NRT effects, but
only a direct depression main effect (F
=4.8, p =.03) was found, suggesting that,
on average, the depressed participants
scored  higher  than  the  non-depressed
participants,  no  matter  the  treatment
condition  was.  (Figure  2)  At  those
specific follow up points, there were no
significant  pair-wise  differences.
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Figure 2.  Average feeling anxious scores by treatment and depression at 1, 7 and 14 days
after cessation baseline scores as covariate.Impact of Nicotine Replacement Therapy on Post-Cessation Mood Profile by Pre-Cessation
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Feeling sad
In feeling sad, there was a depression
main effect (F=9.8, p =.002), but also a
NRT treatment effect (F=4.5, p =.03).
On average, the NRT groups reported
lower sadness scores than the placebo
groups. This was, generally speaking,
slightly  more  visible  among  the
depressed  group,  yet  no  significant
depression  by  NRT  interaction  was
found  (F=3.5,  p=.06).  (Figure  3)
However, based on the Tukey HSD tests,
none of the pair-wise differences at the
specific  time  points  were  significant.
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Figure 3.  Average feeling sad scores by treatment and depression at 1, 7 and 14 days after
cessation baseline scores as covariate.26 Korhonen
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Feeling confused
In feeling confused we found a NRT
main effect (F=9.4, p =.002), indicating
that,  generally  speaking,   those  in
placebo treatment would score higher,  a
depression  main  effect,  (F=14.0,  p
<.001),  suggesting  that  the  depressed
participants had higher scores than the
non-depressed  ones,  and  a  significant
depression by NRT interaction (F=8.2, p
= .005), suggesting that, on average, the
treatment effect was more visible among
the participants scoring high in the pre-
cessation depressive symptoms (Figure
4). According to Tukey HSD tests, pair-
wise differences at those specific time
points were significant at 14 days only.
The  depressed  placebo  group  had
significantly higher mean score than the
non-depressed placebo group (p=.005)
and  the  non-depressed  NRT  group
(p=.01). However, the depressed NRT
group did not have significantly higher
score  than  any  of  the  non-depressed
groups.
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Figure 4.  Average feeling confused scores by treatment and depression at 1, 7 and 14
days after cessation baseline scores as covariate.Impact of Nicotine Replacement Therapy on Post-Cessation Mood Profile by Pre-Cessation
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Feeling angry
In feeling angry we found a modest non-
significant NRT main effect (F=3.5, p
=.06),  a  significant  depression  main
effect,  (F=10.7,  p =.001), but also a
significant  depression  by  NRT
interaction (F=5.5, p = .02), suggesting
that, generally speaking, the treatment
effect  was  more  visible  among  the
participants  scoring  high  in  the  pre-
cessation  depressive  symptoms.
However, according to Tukey HSD tests,
pair-wise differences at those specific
time points were significant only at day
1(p=.04), and almost significant at day 7
(p=.08), the depressed in placebo group
having higher mean score than the non-
depressed in NRT and placebo groups,
whereas the depressed in NRT group did
not have significantly higher score than
any  of  the  non-depressed  groups.  A
significant time effect (F = 4.2, p = .02)
suggested that, on average, there were
differences between the groups only at 1
and  7  days  follow  up  points.
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Figure 5.  Average feeling angry scores by treatment and depression at 1, 7 and 14 days
after cessation baseline scores as covariate.28 Korhonen
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Feeling energetic and fatigue
As  shown  in  Table  3,  no  significant
NRT, baseline depression or time main
effects  or  interactions  were  found  in
these energy-related mood states.
DISCUSSION
The  present  study  evaluated  the
effect of Nicotine Replacement Therapy
(NRT) on the post-quit mood profiles.
The primary hypothesis tested whether
pre-cessation sub-syndromal depression
differentiated NRT’s effects on Profile
of Mood States (POMS), defined as six
post cessation mood states. The results
of the ANCOVA models suggested that
pre-cessation depression modified NRT
effects in some specific mood states. We
found depression by NRT- interaction
effects on feeling confused and feeling
angry.  On  average,  the  depressed
participants in the NRT condition had
lower  symptom  scores  than  those
depressed  ones  in  the  placebo  group,
such  NRT  effects  being  less  visible
among the non-depressed participants. In
other words, the depressed participants
in the placebo groups had the highest
symptom  scores.  However,  those
depressed  in  NRT  conditions  did  not
have  significantly  higher  symptom
scores compared to the non-depressed
groups,  suggesting  that  NRT  may  be
particularly important for those quitters
scoring high in pre-cessation depression.
Effects of NRT
In an earlier study Garvey et al. [24]
found marginal effects of nicotine gum
on  self-reported  post-cessation
symptoms. There was a slight trend for
the  active  gum  users  to  report  less
increase in feeling confused compared to
the placebo participants.  However, the
study  did  not  include  analyses  by
subgroups,  such  as  by  pre-cessation
depressive symptoms. Thus, the present
study was needed to give more insight
into the specific effects of NRT among
such sub-groups.
The form of NRT may play a role in
the effects on the mood states. This trial
used  nicotine  gum  as  a  form  of
treatment. Using some other forms of
NRT, such as nicotine patches, may not
be as effective as nicotine gum in terms
of  some  specific  symptoms,  such  as
mood  effects.  The  nicotine  patches,
although being significantly effective in
terms  of  abstinence,  had  only  slight
effects on measures of mood among the
abstainers [23]. Further, the combination
of nicotine patch and gum was found
significantly  more  effective  in
alleviating withdrawal symptoms than
any single treatment [10].
Also, the dose of NRT may play a
role in those effects examined in our
study.  Initially,  the  participants  were
randomized to NRT (2mg or 4mg), or
placebo groups. This report combined
the two active treatment groups together.
One  may  ask  whether  the  groups
differed in terms of dose, which might
cause bias on the results. We analyzed
this and found no biased effect caused
by  the  nicotine  dose  in  the  active
conditions among the depressed vs. non-
depressed subgroups. First, 79% of the
depressed participants, whereas 75% of
the  non-depressed  were  in  the  NRT
condition (p =.52). Second, among those
depressed  in  the  NRT  group  50%
received  2mg  and  50%  4mg  dose  of
nicotine.  Third,  among  those  non-
depressed  43.7%  were  in  2mg  and
56.3% in 4mg condition (p=.44).Impact of Nicotine Replacement Therapy on Post-Cessation Mood Profile by Pre-Cessation
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Modifying Role of Depressive Symptoms
Our results that smokers with pre-
cessation depressive symptoms would be
a particularly responsive to treatment of
mood and energy related symptoms are
supported by recent findings [30]. They
suggested that one phenotype of tobacco
dependence  can  be  characterized  by
specific  withdrawal  symptomatology,
which is actually primarily driven by
depression.  Although  the  POMS
measures  used  in  our  study  are  not
directly  developed  for  measuring  the
withdrawal  symptoms,  they  -  if
measured  among  the  abstinent
participants - can be used to track similar
signs of withdrawal.
Different  effects  of  NRT  among
depressed and non-depressed smokers
have  been  explained  also  by  genetic
factors,  such  as  by  influence  of  the
dopamine D4 receptor gene. It has been
suggested that genetic factors involved
in  dopamine  transmission  may  be
associated with the beneficial effects of
NRT for depressed smokers [31]. Thus,
those more visible treatment effects for
the depressed than for the non-depressed
smokers  would  be  mediated  by
dopamine  transmission.  This  may
provide an alternative explanation for
our findings, although they were limited
in  two  mood  states  only,  i.e.  feeling
confused and feeling angry.
Methodological Limitations
We  analyzed  the  post-cessation
mood profiles assuming that among the
abstinent  participants  they  represent
similar  signs  as  the  withdrawal
symptoms do after smoking cessation.
We  also  assumed  that  these  mood
profiles are most relevant to be studied
during the early period of abstinence.
Our assumption is supported by Ward et
al.[7] suggesting that the POMS would
be  identified  as  transient  abstinence
effects  during  the  first  month  after
cessation. Following these assumptions,
we restricted our analyses among those
participants only who were abstinent for
at least two weeks.
These  analyses  concern  a  non-
random sample of only those smokers
who were able to achieve a continuous
abstinence of two weeks. The procedure
of including the abstainers only raises
methodological concerns of possible bias
between the original sample (n=608) and
the  sub-sample  used  in  our  analyses
(n=242). The prevalence of the baseline
depressive  symptoms  in  the  original
sample  was  significantly  higher  than
among the participants included in this
secondary analysis. In other words, those
with higher CES-D scores at baseline
had already relapsed before two weeks
and were not included in this analysis.
Actually,  43%  of  non-depressed  and
32% of depressed participants survived
through two weeks. Thus, it seems to be
possible that the direct effect of the pre-
cessation depressive symptoms on post-
cessation mood profile could have been
somewhat diluted in the present study.
The drop-out analysis data in Table 1
also  suggests  that  higher  depression
score,  higher  tobacco  dependence  as
well as ‘feeling sad’ and ‘fatigue’ were,
indeed, associated to relapse before two
weeks. The observations that those with
higher ‘feeling sad’ scores had relapsed
before two weeks are consistent with
previous results [5], where early relapse
was associated with increased negative
mood. However, our observations that
the participants with highest depression
scores had early relapse is contradictory
with a recent meta-analysis suggesting
that depression would not have direct
effect on smoking cessation [13].30 Korhonen
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In this research paper the CES-D was
used as a proxy for depression, rather
than actual medical/psychiatric records
or  APA  diagnostic  criteria.  Thus,  we
have  to  remember  that  the  CES-D  is
indicative  of  sub-clinical  depressive
symptoms,  but  is  not  considered
diagnostic of depression. A limitation of
this study is that we may not have been
able to address the question of whether
NRT is particularly efficacious among
individuals  with  major  depressive
disorder.
As  a  further  limitation  should  be
mentioned  that  the  analysis  of
covariance (ANCOVA), which we used
as the principal technique, assumes that
the variable being analyzed is measured
on  a  continuous  interval  scale  and
follows a normal distribution. Given that
each of the POMS measures were 0 - 4
Likert  scales,  this  may  cause  some
concerns. However, ANCOVA is known
to be very robust to departures from its
assumptions.   
Clinical Significance
Whether or not NRT substantially
reduces post-quit negative mood profiles
more  effectively  for  those  with  sub-
syndromal depression has high clinical
relevance.  It  is  important  to  learn
whether  conventional  treatment
modalities effectively promote smoking
cessation process among this subgroup
of  smokers.  As  mentioned  earlier  the
data  reported  were  collected  on
participants who remained abstinent at
two weeks post-cessation. In order to
appreciate the  clinical significance of
these results, it would be interesting to
know  if  those  mood  states  which
appeared to be influenced by NRT and
pre-cessation depressive symptoms were
subsequently  predictive  of  relapse.
Although  beyond  the  scope  of  the
present research question, we actually
conducted a survival analysis on days
abstained and found that a high ‘Feeling
confused’  score  predicted  relapse
(Hazard Ratio = 1.17; 95% CL = 1.01-
1.35; p=.04). Also, a high ‘Feeling sad’
score was predictive for relapse ((Hazard
Ratio = 1.13), although it did not reach
statistical significance (95% CL = 0.98 -
1.30;  p=.08).   Although  the  evidence
based on these analyses is not strong,
another very recent study gives more
support to the clinical significance of
POMS in smoking cessation. Etter [32]
found that at least some components of
the  mood  profile,  such  as  anxiety,
depression, irritability (especially feeling
angry)  and  difficulty  concentrating
(feeling  confused)  are  associated  to
relapse.
Although not all our results achieved
statistical significance, we would like to
mention  the  possible  clinical
significance of them. For example, one
clinically  relevant  finding  is  that  in
general, those smokers scoring high in
pre-cessation depressive symptoms, if
they  don’t  receive  any  treatment  for
smoking cessation, may be suffering too
much from adverse feelings during the
first  weeks  of  abstinence.  Thus,  in
clinical practice, the level of depressive
symptoms should be evaluated for every
smoker before smoking cessation. If a
patient expressed depressive symptoms
and  is  willing  to  attempt  quitting
cigarettes, a clinician should consider
suggesting  antidepressant  or  NRT  or
combination treatments. Currently there
is no clear evidence suggesting which
antidepressant or form of NRT is the
most effective for those with depressive
symptoms [33, 34]. Advantages of NRT
include  that  it  has  minimal
contraindications  and  it  is  available
over-the-counter in most countries [2].Impact of Nicotine Replacement Therapy on Post-Cessation Mood Profile by Pre-Cessation
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